Glutaone vs Luthione vs Cindella Set: What Is Actually Different?

Editorial method: this guide separates Korean product records, procurement-format questions, FillersFairy inventory facts, peer-reviewed cosmetic evidence and U.S. regulator information. Last evidence review: August 8, 2026. This article has not been medically reviewed.

Scope: this article helps professional buyers and careful researchers distinguish three product formats, understand what the available cosmetic evidence can and cannot prove, and check procurement records before considering a purchase. It does not recommend treatment for any person and intentionally omits dose, dilution, reconstitution, injection technique, route selection, treatment schedule and self-administration instructions.

First, Separate the Product Names

Three layers are often collapsed online: the product name, the active ingredient and the bundle name. Keeping them separate prevents the most important D13 error. Glutaone and Luthione are named products whose records identify reduced glutathione as the active ingredient. Cindella is a different named product whose active is thioctic acid, also called alpha-lipoic acid.

The Cindella Set is the bundle. The FillersFairy listing groups ten Luthione 1200mg units, ten Cindella thioctic-acid ampoules and ten vitamin-C units. Therefore, “1200mg” in the set refers to the Luthione glutathione component. It does not mean that a Cindella ampoule contains 1200mg of glutathione.

This distinction matters for search, purchasing and safety. A buyer who asks only for “Cindella glutathione” may receive a single thioctic-acid product, a three-part set or an inaccurately described listing. The first useful question is not which one is stronger; it is which exact product, ingredient and pack format is being discussed.

Throughout this guide, glutathione injections means products whose active record actually identifies glutathione. The phrase does not automatically include every antioxidant ampoule sold beside them, and it does not convert a multi-component set into one finished medicine. This naming rule keeps the comparison reproducible when packaging, language or reseller descriptions vary.

Glutaone, Luthione and the Cindella Set Compared

The table supports product identification, not a clinical ranking. It does not show that equal nominal strength produces equal outcomes, that the products are interchangeable in every market, or that the Cindella Set is superior because it contains more components. Each additional component adds another product record, medical-history question and market rule to check.

That is also why the comparison does not rank Korean glutathione injections by box color, number of components or headline milligrams. A complete set may be commercially convenient for an established professional program, while a single-ingredient box may be easier to identify and audit. Neither format is automatically the better clinical choice; the intended lawful use and professional assessment remain separate decisions.

Glutaone vs Luthione: What Is Actually Different?

A useful Glutaone vs Luthione comparison begins with what is genuinely shared: both records describe reduced glutathione at 1200mg per vial, and both are presented in ten-vial boxes. That common specification explains why buyers compare them. It does not make the names interchangeable.

The products have different record holders or manufacturers, packaging and market documentation. Their complete labels may also differ in excipients, approved indications, warnings, storage wording and destination-market status. Those fields matter more than packaging color or a reseller’s shortened description. If a listing does not show the exact name, active, pack, lot and market documentation, “1200mg glutathione” is not enough information to close the identity check.

There is no evidence basis in this source package for calling either product purer, safer, stronger in effect or clinically superior. A nominal milligram comparison is a composition fact, not an outcomes trial. The correct conclusion is narrower: Glutaone and Luthione are two distinct finished products with the same listed active strength, while the Cindella Set is a bundle built around Luthione plus two other products.

When a buyer compares glutathione injections, the useful differentiators are therefore documentary: exact legal product name, record holder, active, dosage form, pack, local status and intact batch information. Claims such as “premium,” “stronger whitening” or “clinic favorite” are not substitutes for those fields and are not used in this guide.

Which Format Fits the Procurement Need?

There is no single “best” format for every buyer. A professional procurement team may be trying to stay inside an existing manufacturer record system, reduce the number of SKUs it must reconcile or source a preconfigured multi-product bundle. Those are operational questions, not evidence that one format is clinically superior.

This table is a purchasing-navigation tool, not a clinical-suitability or efficacy ranking. “Format to investigate” means the record that most directly matches the stated procurement need. It does not mean that the product is appropriate for a particular person, indication or treatment plan.

The commercial decision should follow the documentation match. First identify the product or bundle that fits the purchasing brief; then request current availability, quotation and shipping information for that exact record. A lower price or a familiar box color should not be used to switch between products whose documentation has not been reconciled.

What Does the Evidence Say About Cosmetic Claims?

Glutathione is involved in cellular redox chemistry and antioxidant systems. That biochemical role is real, but it cannot by itself establish that injectable supplementation produces a visible, lasting or clinically meaningful cosmetic result. Mechanism, blood level, short-term marker and patient outcome are different levels of evidence.

Many search results compare glutathione injections by delivery speed, expected glow or treatment frequency. Those comparisons move past the evidence question too quickly. Before any product-level conclusion is made, a study must be checked for formulation, population, comparator, outcome measure, follow-up and adverse events. Evidence from one route or formulation cannot simply be transferred to another branded product.

The most directly relevant placebo-controlled cosmetic study was small and did not test Glutaone, Luthione or the Cindella Set. Of 50 enrolled participants, 32 completed the study. Improvement was reported for 6 of 16 participants in the active group and 3 of 16 in the placebo group, a difference that did not meet the conventional threshold for statistical significance. The apparent effect largely faded after treatment stopped. The study also reported abnormal liver tests and one anaphylactic reaction among participants who were removed from the final comparison. Read the original placebo-controlled study for the complete design and limitations.

A 2025 systematic review indexed by PubMed found only one placebo-controlled intravenous study and concluded that the IV route was not supported for skin lightening because efficacy was inadequate and adverse effects were material. This does not mean that every glutathione product has the same risk profile; it means the available cosmetic evidence cannot responsibly support a whitening guarantee, a permanent-result claim or a product-superiority claim.

Regulatory Status Depends on Product, Use and Market

“Registered,” “approved” and “commonly used” are not global labels. A Korean product record is evidence about that product in Korea or an identified export market. It does not establish U.S., UK, EU or another destination’s approval, lawful import status, permitted indication or professional scope.

For internationally sourced glutathione injections, the destination market is the controlling question. A product may have a legitimate record in one country yet lack the authorization, labeling or supply pathway required in another. Buyers should verify the exact product and intended use with the relevant regulator or qualified local professional rather than relying on a seller’s global approval badge.

The Korean records also show why cosmetic claims need separation. Daehan Nupharm identifies Luthione 1200mg as reduced glutathione and lists a medical indication related to prevention of neurological disorders caused by cisplatin or similar chemotherapy. Its Cindella record identifies thioctic acid and different medical indications. Neither record is a clinical endorsement of cosmetic skin lightening, and the two products should not be merged into one active ingredient.

In the United States, the FDA’s 2022 Pharmacy Compounding Advisory Committee materials identified significant safety concerns for injectable glutathione, found insufficient evidence across proposed uses and concluded that the balance of its criteria weighed against adding glutathione to the 503A bulk drug substances list. That is a specific U.S. compounding assessment. It should not be rewritten as a worldwide ban, a recall of these Korean products or proof of another country’s rules.

An earlier FDA compounding risk alert investigated adverse events linked to compounded injections made with glutathione material that had been supplied for dietary use and contained excessive bacterial endotoxin. The alert did not test Glutaone, Luthione or Cindella. Its relevance here is the procurement lesson: ingredient grade, intended route, sterile manufacturing controls and source documentation cannot be inferred from the word “glutathione” or from a certificate image alone.

Risks and Why Glutathione Injections Are Not a Self-Use Guide

Injectable products add risks that do not exist in the same way for ordinary packaged consumer goods. Hypersensitivity and anaphylaxis are possible; the small cosmetic study also reported abnormal liver tests and other adverse effects. Product quality failures can introduce contamination or endotoxin. Combining products adds further questions about medical history, compatibility, interactions and monitoring.

These concerns apply to the category of glutathione injections without proving that a particular unopened unit is defective. Risk communication should preserve both facts: serious reactions and quality failures have been documented, and the cited incidents did not test every current Korean brand. Product-specific records and professional oversight are still necessary.

Those risks cannot be solved by choosing a popular brand or matching a box photograph. A qualified professional needs the exact product record, the person’s medical history, the intended use, the controlling local rules and a setting prepared to respond to an adverse reaction. This article does not decide whether glutathione injections are appropriate for any individual.

For the same reason, no administration recipe appears here. A product page or comparison guide should not tell a consumer what to mix, how much to use, which route to choose, where to inject or how often to repeat a treatment. If a listing makes those steps look routine, that is a reason to pause rather than a substitute for professional assessment.

Professional Procurement Checks for Glutathione Injections

Procurement review should confirm that the product arriving is the product that was evaluated. A clean photograph, a low price or a positive review cannot close that chain. Use the exact package and market documentation, and place the order on hold when the evidence does not reconcile.

A generic “KFDA” sticker, reseller certificate or QR image is not independent proof of authenticity or lawful use. It can be one clue, but the product name, Korean record, batch details, destination rules and physical pack still need to agree. For a Cindella Set, also confirm that all three named components are present and separately identified.

Professional procurement of glutathione injections should also preserve the evidence after delivery: invoice, supplier identity, received lot, expiry, condition on arrival and any complaint correspondence. That record does not replace clinical governance, but it makes a mismatch traceable and prevents a later product question from depending on memory or a deleted seller page.

Related Product Identity Content

The three product records linked in the procurement table are the primary next step for an active sourcing comparison. Two additional internal records can help readers understand the Cindella Set without merging its components:

• Existing Cindella editorial for earlier brand context. Its broader narrative does not replace the identity, evidence and market checks in this guide.
• DHNP Vitamin C component record for the separately listed vitamin-C product used in the set configuration. It remains a distinct product record, not proof that the bundle is one finished medicine.

Future verification, storage/authenticity, vitamin-C identity and alpha-lipoic-acid guides should link back to this comparison after those pages are created and fact-checked. This draft does not publish placeholder or dead links.

Frequently Asked Questions

Is Cindella a glutathione injection?

No. The Cindella product record identifies thioctic acid, also called alpha-lipoic acid. The Cindella Set includes a separate Luthione 1200mg reduced-glutathione component plus Cindella and vitamin C. The set name should not be used to relabel the Cindella ampoule as glutathione.

Are Glutaone and Luthione the same product?

No. Both are listed as reduced glutathione at 1200mg per vial and both come in ten-vial boxes, but they are distinct named products with different record holders or manufacturers and product documentation. Equal nominal strength does not prove finished-product interchangeability or equal clinical outcomes.

What does 1200mg mean in the Cindella Set?

It refers to the reduced-glutathione content of the Luthione component. Cindella is the thioctic-acid component, and vitamin C is the third product in the set. A complete listing should identify all three separately instead of presenting Cindella itself as a 1200mg glutathione vial.

Are these products FDA approved for skin whitening?

The Korean records and FillersFairy listings do not establish U.S. FDA approval for cosmetic skin lightening. The FDA’s glutathione review identified substantial evidence and safety concerns in the U.S. compounding context. Approval, prescribing and import status must be checked for the exact product, use and destination market.

Does research prove that glutathione injections permanently lighten skin?

No. The small placebo-controlled intravenous study did not show a statistically clear advantage, and its apparent effect largely faded after treatment stopped. A 2025 systematic review also found the IV evidence inadequate and adverse-effect concerns material. Neither source tested the three named D13 products as a permanent cosmetic treatment.

Can glutathione injections be self-administered?

This guide does not support self-administration. Injectable-product identity, medical history, legal prescribing, interactions, sterility and emergency readiness require qualified professional oversight. Do not use a product comparison, seller page or online recipe as an injection plan.

What should a professional buyer verify before purchase?

Verify the exact product name, active, strength, record holder or manufacturer, destination-market status, lot, expiry, seals, label-matched storage and supplier traceability. For the Cindella Set, confirm all three components and counts. Put the order on hold when the invoice, record and physical pack do not reconcile.